Treatment OutcomeRetrospective StudiesMedian EminenceFollow-Up StudiesProspective StudiesTime FactorsSurvival AnalysisAntineoplastic Combined Chemotherapy ProtocolsSurvival RatePrognosisDisease-Free SurvivalMedian NeuropathyDrug Administration ScheduleCombined Modality TherapyKaplan-Meier EstimateRisk FactorsCohort StudiesNeoplasm StagingNeoplasm Recurrence, LocalRecurrenceDisease ProgressionAntineoplastic AgentsProportional Hazards ModelsRemission InductionCisplatinPredictive Value of TestsCyclophosphamideMultivariate AnalysisFluorouracilInfusions, IntravenousStatistics, NonparametricSalvage TherapyLung NeoplasmsBreast NeoplasmsDeoxycytidineRisk AssessmentIncidenceAge FactorsDoxorubicinBiological MarkersVincristineSeverity of Illness IndexNeoplasm MetastasisInfant, NewbornTransplantation, AutologousFeasibility StudiesAdenocarcinomaEtoposidePilot ProjectsChemotherapy, AdjuvantDose-Response Relationship, DrugBrain NeoplasmsPaclitaxelDouble-Blind MethodHIV InfectionsTreatment FailureRadiotherapy DosagePostoperative ComplicationsHematopoietic Stem Cell TransplantationCase-Control StudiesLength of StayPrednisoneSensitivity and SpecificityCarboplatinVinblastineAcute DiseaseAdministration, OralTomography, X-Ray ComputedReproducibility of ResultsMethotrexateLymphoma, Non-HodgkinDrug Therapy, CombinationLeucovorinNeutropeniaAntibodies, Monoclonal, HumanizedOrganoplatinum CompoundsLiver NeoplasmsAntimetabolites, AntineoplasticCross-Sectional StudiesRadiotherapy, AdjuvantChi-Square DistributionPregnancyCarcinoma, Non-Small-Cell LungAntineoplastic Agents, AlkylatingUnited StatesCytarabineColorectal NeoplasmsTransplantation, HomologousAntibodies, MonoclonalMelphalanTumor Markers, BiologicalMultiple MyelomaRadiotherapyCD4 Lymphocyte CountDacarbazineSternotomyCamptothecinPalliative CareDrug EvaluationLymphatic Metastasis